CAD 0.66
(4.76%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 44.29 Million CAD | 614.6% |
2022 | 6.19 Million CAD | -50.75% |
2021 | 12.58 Million CAD | 1014.37% |
2020 | 1.12 Million CAD | 5.22% |
2019 | 1.07 Million CAD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 33.19 Million CAD | -13.23% |
2024 Q1 | 38.25 Million CAD | -13.64% |
2023 FY | 44.29 Million CAD | 614.6% |
2023 Q2 | 53.07 Million CAD | 652.99% |
2023 Q1 | 7.04 Million CAD | 13.7% |
2023 Q3 | 48.67 Million CAD | -8.28% |
2023 Q4 | 44.29 Million CAD | -8.99% |
2022 Q3 | 10.22 Million CAD | 0.0% |
2022 Q4 | 6.19 Million CAD | -39.36% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Appili Therapeutics Inc. | 1.49 Million CAD | -2872.216% |
Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | -65.767% |
Helix BioPharma Corp. | 1.48 Million CAD | -2875.017% |
Microbix Biosystems Inc. | 35.65 Million CAD | -24.248% |
Medicenna Therapeutics Corp. | 19.13 Million CAD | -131.515% |
Oncolytics Biotech Inc. | 38.82 Million CAD | -14.111% |
Sernova Corp. | 22.1 Million CAD | -100.382% |